New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.41-1.59 (-9.35%)
At close: 04:00PM EST
15.35 -0.06 (-0.39%)
After hours: 07:45PM EST

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th floor
New York, NY 10001
United States
646 747 1000
https://www.interceptpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees498

Key executives

NameTitlePayExercisedYear born
Mr. Jerome B. DursoPres, CEO & Director853.17kN/A1968
Dr. Mark Pruzanski M.D.Founder, Advisor & Director1.3MN/A1968
Mr. Andrew SaikChief Financial OfficerN/AN/A1969
Mr. Bryan BallChief Quality Officer & Sr. VP of OperationsN/AN/A1970
Mr. Rocco VeneziaChief Accounting Officer & TreasurerN/AN/AN/A
Ms. Lisa M. DeFrancescoSr. VP of Corp. Affairs & Investor RelationsN/AN/A1980
Mr. Jared M. Freedberg J.D.Gen. CounselN/AN/A1968
Mr. David FordChief HR OfficerN/AN/A1970
Dr. Gail CawkwellSr. VP of Medical Affairs, Safety & Pharmacovigilance and Acting Chief Medical OfficerN/AN/A1963
Ms. Linda M. RichardsonExec. VP & Chief Commercial OfficerN/AN/A1964
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.

Corporate governance

Intercept Pharmaceuticals, Inc.’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.